Sera Prognostics (SERA) said Monday it launched a proposed offering of its Class A common stock and pre-funded warrants to purchase the common stock.
The company said it intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total amount of shares sold in the offering.
Sera is offering all shares and warrants in this sale, though it has not yet disclosed the total size of the offering.
Proceeds from the offering are expected to support the company's commercial expansion in the US, preparations for entry into the European market, and further research aimed at increasing adoption of its PreTRM test, which assesses the risk of spontaneous preterm birth in certain pregnancies.
Shares of Sera Prognostics were down nearly 7% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.